Download PDF
PiD - Psychotherapie im Dialog 2015; 16(03): 75-80
DOI: 10.1055/s-0041-102180
Aus der Praxis
© Georg Thieme Verlag KG Stuttgart · New York

Neuroleptika minimal

Dosisabhängige Risiken der medikamentösen Therapie bei Psychosen
Volkmar Aderhold
Further Information

Publication History

Publication Date:
07 September 2015 (online)

Also available at
    Permissions and Reprints

Neuroleptika wirken nicht kurativ. Neben somatischen und ­hormonalen Nebenwirkungen werden ihre neurotoxischen Effekte immer offensichtlicher. Daher gilt für sie nicht die oft suggerierte Alltagslogik des „mehr hilft mehr“, sondern ein „weniger ist mehr“.

 

  • Literatur

  • Aderhold V, Weinmann S, Hägele C, Heinz A. Frontale Hirnvolumenminderung durch Antipsychotika?. Nervenarzt 2015; 86: 302-323 im Internet http://link.springer.com/article/10.1007/s00115-014-4027-5
    CrossrefPubMedGoogle Scholar
  • American Psychiatric Association Im Internet http://www.choosingwisely.org/wp-content/uploads/2015/02/APA-Choosing-Wisely-List.pdf
    PubMed
  • Carpenter Jr WT, Buchanan RW, Kirkpatrick B, Breier AF. Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry 1999; 156: 299-303
    PubMedGoogle Scholar
  • Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24: 192-208
    Google Scholar
  • De Hert M, Cohen D, Bobes J et al Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011; 10: 138-151
    CrossrefPubMedGoogle Scholar
  • Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) Leitlinien Schizophrenie. letzte Überarbeitung Nov 2005
    PubMed
  • Essock SM, Schooler NR, Stroup TS et al. Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011; 168: 702-708
    Google Scholar
  • Fusar-Poli P, Smieskova R, Kempton MJ et al. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 2013; 37: 1680-1691
    CrossrefPubMedGoogle Scholar
  • Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology 2009; 34: 662-671
    CrossrefPubMedGoogle Scholar
  • Götzsche P. Deadly medicines and organized crime. How big pharma has corrupted healthcare. New York: Radcliffe: 2013
    Google Scholar
  • Harrow M, Jobe TH, Faull RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med 2012; 42: 2145-2155
    CrossrefPubMedGoogle Scholar
  • Hori H, Yoshimura R, Katsuki A et al. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. J Psychiatr Res 2013; 47: 1843-1848
    CrossrefPubMedGoogle Scholar
  • Husa AP et al. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia—An observational 9-year follow-up study. Schizophrenia Research 2014; 158: 134-141
    CrossrefPubMedGoogle Scholar
  • Lepping P, Sambhi RS, Whittington R et al. Clinical relevance of findings in trials of antipsychotics: systematic review. Br J Psychiatry 2011; 198: 341-345
    CrossrefPubMedGoogle Scholar
  • Leucht S, Arbter D, Engel RR et al. How effective are second-generation antipsychotic drugs?. Molecular Psychiatry 2009; 14: 429-447
    CrossrefPubMedGoogle Scholar
  • Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull 2010; 36: 624-632
    CrossrefPubMedGoogle Scholar
  • Levine SZ, Rabinowitz J, Faries D et al. Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. Schizophr Res 2012; 137: 141-146
    CrossrefPubMedGoogle Scholar
  • Radua J, Borgwardt S, Crescini A et al. Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neuroscience and Biobehavioral Reviews. Neurosci Biobehav 2012; 36: 2325-2333
    CrossrefPubMedGoogle Scholar
  • Samaha A-N. Can antipsychotic treatment contribute to drug addiction in schizophrenia?. Prog Neuropsychopharmacol Biol Psychiatry 2014; 52: 9-16
    CrossrefPubMedGoogle Scholar
  • Samaha AN, Reckless GE, Seeman P et al. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 2008; 64: 145-152
    CrossrefPubMedGoogle Scholar
  • Seeman P, Weinshenker D, Quirion R et al. Dopamine supersensitivity correlates with D2 High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 2005; 102: 3513-3518
    CrossrefPubMedGoogle Scholar
  • Seeman P, Schwarz J, Chen JF et al. Psychosis pathways converge via D2 high dopamine receptors. Synapse 2006; 60: 319-346
    CrossrefPubMedGoogle Scholar
  • Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated Dopamine D2High receptors. CNS Neurosci Ther 2011; 17: 118-132
    CrossrefPubMedGoogle Scholar
  • Suzuki T, Uchida H, Tanaka KF et al. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Int Clin Psychopharmacol 2003; 18: 323-329
    CrossrefPubMedGoogle Scholar
  • Suzuki T, Uchida H, Tanaka KF et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 2004; 7: 133-142
    CrossrefPubMedGoogle Scholar
  • Wunderink L, Nieboer RM, Wiersma D et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013; 70: 913-920
    CrossrefPubMedGoogle Scholar
  • Wunderink L, Nienhuis FJ, Sytema S et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007; 68: 654-661
    CrossrefPubMedGoogle Scholar